Low-Dose Hydrocortisone Led to Cognitive Benefits in Women With HIV

A recent randomized trial revealed that low-dose hydrocortisone (LDH) could enhance certain cognitive functions in women with HIV who have suppressed viral loads. After a single 10-milligram oral dose, participants showed significant improvements in learning and attention scores at various time points. After four weeks of daily LDH treatment, there was a notable improvement in delayed recall, although the interaction between treatment and time was not statistically significant.

Both groups demonstrated improvements in executive function, but no significant differences were observed for total learning, working memory, or attention in either group. The study's authors suggest that transient modulation of the HPA axis, which can be achieved through LDH, may boost domain-specific cognitive functions like verbal learning, memory, and attention in individuals affected by chronic stress, psychiatric comorbidities, and cognitive impairment.

However, they emphasize that LDH is more likely a mechanism or proof-of-concept intervention, rather than a long-term corticosteroid treatment strategy. The trial, conducted between 2017 and 2023, involved 81 women with HIV and found no serious adverse events related to LDH use. Common side effects included sleep issues and changes in energy levels.

Limitations of the study included its small sample size, which prevented the detection of acute and sustained cognitive effects, and the inability to identify response modifiers based on stress burden or psychiatric symptoms.